Stephen P. Hack, PhD

Affiliations: 
GSK, Rixensart, Wallonie, Belgium 
Google:
"Stephen Hack"
Mean distance: 15.71 (cluster 17)
 
SNBCP

Parents

Sign in to add mentor
John Gordon Ralph Jefferys grad student 1998-2001 University of Birmingham
 (Wellcome Prize Student)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Hack SP, Zhu AX. (2021) Atezolizumab: an investigational agent for the treatment of biliary tract cancer. Expert Opinion On Investigational Drugs
Hack SP, Verret W, Mulla S, et al. (2021) IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Therapeutic Advances in Medical Oncology. 13: 17588359211036544
Hack SP, Zhu AX, Wang Y. (2020) Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Frontiers in Immunology. 11: 598877
Lee MS, Ryoo BY, Hsu CH, et al. (2020) Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. The Lancet. Oncology. 21: 808-820
Hack SP, Spahn J, Chen M, et al. (2020) IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncology (London, England)
Bendell JC, Hochster H, Hart LL, et al. (2017) A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. The Oncologist
Shah MA, Bang YJ, Lordick F, et al. (2016) Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. Jama Oncology
Han K, Jin JY, Marchand M, et al. (2015) Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. Cancer Chemotherapy and Pharmacology
Ascierto PA, McArthur GA, Dréno B, et al. (2015) coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF (V600) mutation-positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519). Journal of Translational Medicine. 13: 2061
Larkin J, Ascierto PA, Dréno B, et al. (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. The New England Journal of Medicine. 371: 1867-76
See more...